Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial

de Graaf, H., Payne, R.O., Taylor, I. et al. (25 more authors) (2021) Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial. Frontiers in Immunology, 12. 694759.



  • de Graaf, H.
  • Payne, R.O. ORCID logo
  • Taylor, I.
  • Miura, K.
  • Long, C.A.
  • Elias, S.C.
  • Zaric, M.
  • Minassian, A.M.
  • Silk, S.E.
  • Li, L.
  • Poulton, I.D.
  • Baker, M.
  • Draper, S.J.
  • Gbesemete, D.
  • Brendish, N.J.
  • Martins, F.
  • Marini, A.
  • Mekhaiel, D.
  • Edwards, N.J.
  • Roberts, R.
  • Vekemans, J.
  • Moyle, S.
  • Faust, S.N.
  • Berrie, E.
  • Lawrie, A.M.
  • Hill, F.
  • Hill, A.V.S.
  • Biswas, S.
Copyright, Publisher and Additional Information: © 2021 de Graaf, Payne, Taylor, Miura, Long, Elias, Zaric, Minassian, Silk, Li, Poulton, Baker, Draper, Gbesemete, Brendish, Martins, Marini, Mekhaiel, Edwards, Roberts, Vekemans, Moyle, Faust, Berrie, Lawrie, Hill, Hill and Biswas. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY)( The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Keywords: Pfs25; malaria; transmission-blocking; IMX313; vaccine
  • Accepted: 29 June 2021
  • Published (online): 14 July 2021
  • Published: 14 July 2021
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > Department of Infection and Immunity (Sheffield)
Depositing User: Symplectic Sheffield
Date Deposited: 25 Jul 2021 22:59
Last Modified: 25 Jul 2021 22:59
Status: Published
Publisher: Frontiers Media SA
Refereed: Yes
Identification Number: